Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
CONTEXT Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function...
Saved in:
| Published in | JAMA : the journal of the American Medical Association Vol. 306; no. 20; pp. 2221 - 2228 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chicago, IL
American Medical Association
23.11.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0098-7484 1538-3598 1538-3598 |
| DOI | 10.1001/jama.2011.1703 |
Cover
| Abstract | CONTEXT Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes. DESIGN, SETTING, AND PATIENTS ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011. INTERVENTIONS Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes) were to receive 75, 150, 225, and 300 mg daily. MAIN OUTCOME MEASURES Platelet function test results (vasodilator-stimulated phosphoprotein [VASP] phosphorylation and VerifyNow P2Y12 assays) and adverse events. RESULTS With 75 mg daily, CYP2C19*2 heterozygotes had significantly higher on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI]: mean, 70.0%; 95% CI, 66.0%-74.0%, vs 57.5%; 95% CI, 55.1%-59.9%, and VerifyNow P2Y12 reaction units [PRU]: mean, 225.6; 95% CI, 207.7-243.4, vs 163.6; 95% CI, 154.4-173.9; P < .001 for both comparisons). Among CYP2C19*2 heterozygotes, doses up to 300 mg daily significantly reduced platelet reactivity, with VASP PRI decreasing to 48.9% (95% CI, 44.6%-53.2%) and PRU to 127.5 (95% CI, 109.9-145.2) (P < .001 for trend across doses for both). Whereas 52% of CYP2C19*2 heterozygotes were nonresponders (≥230 PRU) with 75 mg of clopidogrel, only 10% were nonresponders with 225 or 300 mg (P < .001 for both). Clopidogrel, 225 mg daily, reduced platelet reactivity in CYP2C19*2 heterozygotes to levels achieved with standard clopidogrel, 75 mg, in noncarriers (mean ratios of platelet reactivity, VASP PRI, 0.92; 90% CI, 0.85-0.99, and PRU, 0.94; 90% CI, 0.84-1.04). In CYP2C19*2 homozygotes, even with 300 mg daily of clopidogrel, mean VASP PRI was 68.3% (95% CI, 44.9%-91.6%) and mean PRU, 287.0 (95% CI, 170.2-403.8). CONCLUSION Among patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01235351 |
|---|---|
| AbstractList | Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.CONTEXTVariants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes.OBJECTIVETo test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes.ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011.DESIGN, SETTING, AND PATIENTSELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011.Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes) were to receive 75, 150, 225, and 300 mg daily.INTERVENTIONSMaintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes) were to receive 75, 150, 225, and 300 mg daily.Platelet function test results (vasodilator-stimulated phosphoprotein [VASP] phosphorylation and VerifyNow P2Y(12) assays) and adverse events.MAIN OUTCOME MEASURESPlatelet function test results (vasodilator-stimulated phosphoprotein [VASP] phosphorylation and VerifyNow P2Y(12) assays) and adverse events.With 75 mg daily, CYP2C19*2 heterozygotes had significantly higher on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI]: mean, 70.0%; 95% CI, 66.0%-74.0%, vs 57.5%; 95% CI, 55.1%-59.9%, and VerifyNow P2Y(12) reaction units [PRU]: mean, 225.6; 95% CI, 207.7-243.4, vs 163.6; 95% CI, 154.4-173.9; P < .001 for both comparisons). Among CYP2C19*2 heterozygotes, doses up to 300 mg daily significantly reduced platelet reactivity, with VASP PRI decreasing to 48.9% (95% CI, 44.6%-53.2%) and PRU to 127.5 (95% CI, 109.9-145.2) (P < .001 for trend across doses for both). Whereas 52% of CYP2C19*2 heterozygotes were nonresponders (≥230 PRU) with 75 mg of clopidogrel, only 10% were nonresponders with 225 or 300 mg (P < .001 for both). Clopidogrel, 225 mg daily, reduced platelet reactivity in CYP2C19*2 heterozygotes to levels achieved with standard clopidogrel, 75 mg, in noncarriers (mean ratios of platelet reactivity, VASP PRI, 0.92; 90% CI, 0.85-0.99, and PRU, 0.94; 90% CI, 0.84-1.04). In CYP2C19*2 homozygotes, even with 300 mg daily of clopidogrel, mean VASP PRI was 68.3% (95% CI, 44.9%-91.6%) and mean PRU, 287.0 (95% CI, 170.2-403.8).RESULTSWith 75 mg daily, CYP2C19*2 heterozygotes had significantly higher on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI]: mean, 70.0%; 95% CI, 66.0%-74.0%, vs 57.5%; 95% CI, 55.1%-59.9%, and VerifyNow P2Y(12) reaction units [PRU]: mean, 225.6; 95% CI, 207.7-243.4, vs 163.6; 95% CI, 154.4-173.9; P < .001 for both comparisons). Among CYP2C19*2 heterozygotes, doses up to 300 mg daily significantly reduced platelet reactivity, with VASP PRI decreasing to 48.9% (95% CI, 44.6%-53.2%) and PRU to 127.5 (95% CI, 109.9-145.2) (P < .001 for trend across doses for both). Whereas 52% of CYP2C19*2 heterozygotes were nonresponders (≥230 PRU) with 75 mg of clopidogrel, only 10% were nonresponders with 225 or 300 mg (P < .001 for both). Clopidogrel, 225 mg daily, reduced platelet reactivity in CYP2C19*2 heterozygotes to levels achieved with standard clopidogrel, 75 mg, in noncarriers (mean ratios of platelet reactivity, VASP PRI, 0.92; 90% CI, 0.85-0.99, and PRU, 0.94; 90% CI, 0.84-1.04). In CYP2C19*2 homozygotes, even with 300 mg daily of clopidogrel, mean VASP PRI was 68.3% (95% CI, 44.9%-91.6%) and mean PRU, 287.0 (95% CI, 170.2-403.8).Among patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition.CONCLUSIONAmong patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition.clinicaltrials.gov Identifier: NCT01235351.TRIAL REGISTRATIONclinicaltrials.gov Identifier: NCT01235351. Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes. ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011. Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes) were to receive 75, 150, 225, and 300 mg daily. Platelet function test results (vasodilator-stimulated phosphoprotein [VASP] phosphorylation and VerifyNow P2Y(12) assays) and adverse events. With 75 mg daily, CYP2C19*2 heterozygotes had significantly higher on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI]: mean, 70.0%; 95% CI, 66.0%-74.0%, vs 57.5%; 95% CI, 55.1%-59.9%, and VerifyNow P2Y(12) reaction units [PRU]: mean, 225.6; 95% CI, 207.7-243.4, vs 163.6; 95% CI, 154.4-173.9; P < .001 for both comparisons). Among CYP2C19*2 heterozygotes, doses up to 300 mg daily significantly reduced platelet reactivity, with VASP PRI decreasing to 48.9% (95% CI, 44.6%-53.2%) and PRU to 127.5 (95% CI, 109.9-145.2) (P < .001 for trend across doses for both). Whereas 52% of CYP2C19*2 heterozygotes were nonresponders (≥230 PRU) with 75 mg of clopidogrel, only 10% were nonresponders with 225 or 300 mg (P < .001 for both). Clopidogrel, 225 mg daily, reduced platelet reactivity in CYP2C19*2 heterozygotes to levels achieved with standard clopidogrel, 75 mg, in noncarriers (mean ratios of platelet reactivity, VASP PRI, 0.92; 90% CI, 0.85-0.99, and PRU, 0.94; 90% CI, 0.84-1.04). In CYP2C19*2 homozygotes, even with 300 mg daily of clopidogrel, mean VASP PRI was 68.3% (95% CI, 44.9%-91.6%) and mean PRU, 287.0 (95% CI, 170.2-403.8). Among patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition. clinicaltrials.gov Identifier: NCT01235351. CONTEXT Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. OBJECTIVE To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes. DESIGN, SETTING, AND PATIENTS ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011. INTERVENTIONS Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes) were to receive 75, 150, 225, and 300 mg daily. MAIN OUTCOME MEASURES Platelet function test results (vasodilator-stimulated phosphoprotein [VASP] phosphorylation and VerifyNow P2Y12 assays) and adverse events. RESULTS With 75 mg daily, CYP2C19*2 heterozygotes had significantly higher on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI]: mean, 70.0%; 95% CI, 66.0%-74.0%, vs 57.5%; 95% CI, 55.1%-59.9%, and VerifyNow P2Y12 reaction units [PRU]: mean, 225.6; 95% CI, 207.7-243.4, vs 163.6; 95% CI, 154.4-173.9; P < .001 for both comparisons). Among CYP2C19*2 heterozygotes, doses up to 300 mg daily significantly reduced platelet reactivity, with VASP PRI decreasing to 48.9% (95% CI, 44.6%-53.2%) and PRU to 127.5 (95% CI, 109.9-145.2) (P < .001 for trend across doses for both). Whereas 52% of CYP2C19*2 heterozygotes were nonresponders (≥230 PRU) with 75 mg of clopidogrel, only 10% were nonresponders with 225 or 300 mg (P < .001 for both). Clopidogrel, 225 mg daily, reduced platelet reactivity in CYP2C19*2 heterozygotes to levels achieved with standard clopidogrel, 75 mg, in noncarriers (mean ratios of platelet reactivity, VASP PRI, 0.92; 90% CI, 0.85-0.99, and PRU, 0.94; 90% CI, 0.84-1.04). In CYP2C19*2 homozygotes, even with 300 mg daily of clopidogrel, mean VASP PRI was 68.3% (95% CI, 44.9%-91.6%) and mean PRU, 287.0 (95% CI, 170.2-403.8). CONCLUSION Among patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01235351 Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. Here, Mega et al test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes. |
| Author | Pencina, Michael J Kereiakes, Dean J Sabatine, Marc S Frelinger, Andrew L Ruff, Christian T Hochholzer, Willibald Longtine, Janina A Rogers, William J Mega, Jessica L Isserman, Steven Scirica, Benjamin M Kluk, Michael J Contant, Charles Angiolillo, Dominick J Michelson, Alan D |
| Author_xml | – sequence: 1 givenname: Jessica L surname: Mega fullname: Mega, Jessica L – sequence: 2 givenname: Willibald surname: Hochholzer fullname: Hochholzer, Willibald – sequence: 3 givenname: Andrew L surname: Frelinger fullname: Frelinger, Andrew L – sequence: 4 givenname: Michael J surname: Kluk fullname: Kluk, Michael J – sequence: 5 givenname: Dominick J surname: Angiolillo fullname: Angiolillo, Dominick J – sequence: 6 givenname: Dean J surname: Kereiakes fullname: Kereiakes, Dean J – sequence: 7 givenname: Steven surname: Isserman fullname: Isserman, Steven – sequence: 8 givenname: William J surname: Rogers fullname: Rogers, William J – sequence: 9 givenname: Christian T surname: Ruff fullname: Ruff, Christian T – sequence: 10 givenname: Charles surname: Contant fullname: Contant, Charles – sequence: 11 givenname: Michael J surname: Pencina fullname: Pencina, Michael J – sequence: 12 givenname: Benjamin M surname: Scirica fullname: Scirica, Benjamin M – sequence: 13 givenname: Janina A surname: Longtine fullname: Longtine, Janina A – sequence: 14 givenname: Alan D surname: Michelson fullname: Michelson, Alan D – sequence: 15 givenname: Marc S surname: Sabatine fullname: Sabatine, Marc S |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24818365$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22088980$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10c9rFDEUB_AgFbutXj14kCAUT7vm18wkR53WKhQs_kA8DW8zSZslm6xJtrDH_udm2LVCwVwCj883P947QUchBoPQS0oWlBD6bgVrWDBC6YJ2hD9BM9pwOeeNkkdoRoiS805IcYxOcl6RuijvnqFjxoiUSpIZuj-P2YUb3Pu4cWO8ScbjD5DNiGPA_a9r1lOFL02IZbcxGMKIy63BF9YaXSZy7aEYbwr-akAXd-fKDrtahuJMKBn_dOUWfyuw9Ab3kEYX7yDrrYeEz1029abn6KkFn82Lw36Kfny8-N5_ml99ufzcv7-aA-9ImVvZUA1UALOKtoY0GqzVSls9duOodLtkQjV2qcaGdURI29KWAedLq1jLu46forf7czcp_t6aXIa1y9p4D8HEbR4UaVTLOGVVvnkkV3GbQn1cRUooJZis6PUBbZdrMw6b5NaQdsPf1lZwdgD1w-BtgqBd_ueEpJK3TXWLvdMp5pyMfSCUDNOMh2nGwzTjYZpxDYhHAe1K7XcMJYHz_4-92sem8sMVlIi2FfwP_NyyTg |
| CODEN | JAMAAP |
| CitedBy_id | crossref_primary_10_1002_cpt_2357 crossref_primary_10_1007_s12265_012_9421_4 crossref_primary_10_1016_j_ygeno_2013_01_005 crossref_primary_10_17802_2306_1278_2022_11_3_17_28 crossref_primary_10_1161_CIRCRESAHA_115_306360 crossref_primary_10_33678_cor_2019_069 crossref_primary_10_1111_jcpt_13665 crossref_primary_10_3390_genes14112057 crossref_primary_10_1016_j_ejim_2021_05_022 crossref_primary_10_1038_nbt_2424 crossref_primary_10_1093_eurheartj_suv024 crossref_primary_10_1093_eurheartj_suv025 crossref_primary_10_1161_CIRCINTERVENTIONS_112_972463 crossref_primary_10_1016_j_ejvs_2015_09_020 crossref_primary_10_1016_j_jacc_2014_02_613 crossref_primary_10_5482_HAMO_13_08_0044 crossref_primary_10_1160_TH14_03_0238 crossref_primary_10_36011_cpp_2019_1_e3 crossref_primary_10_17802_2306_1278_2019_8_4_26_36 crossref_primary_10_2217_pme_14_16 crossref_primary_10_3904_kjim_2017_363 crossref_primary_10_1177_1076029616648408 crossref_primary_10_1016_j_jcin_2024_08_027 crossref_primary_10_1016_S2213_2600_13_70134_6 crossref_primary_10_2491_jjsth_23_352 crossref_primary_10_1016_j_crvasa_2012_08_003 crossref_primary_10_1007_s40262_013_0105_2 crossref_primary_10_1080_23808993_2022_2028548 crossref_primary_10_1016_j_ijcard_2024_132418 crossref_primary_10_3174_ajnr_A3405 crossref_primary_10_1161_CIRCRESAHA_117_310965 crossref_primary_10_2217_pgs_14_180 crossref_primary_10_1016_j_ahj_2012_10_008 crossref_primary_10_1016_j_recesp_2014_01_013 crossref_primary_10_1002_rth2_12122 crossref_primary_10_1007_s10354_012_0148_2 crossref_primary_10_1517_14656566_2012_666524 crossref_primary_10_1016_j_rec_2011_11_001 crossref_primary_10_2147_CPAA_S242675 crossref_primary_10_1038_s44355_024_00012_w crossref_primary_10_1172_JCI129203 crossref_primary_10_1080_20009666_2017_1347475 crossref_primary_10_1177_2042098613485595 crossref_primary_10_1111_j_1538_7836_2011_04604_x crossref_primary_10_1007_s00101_012_2012_6 crossref_primary_10_1080_14796678_2024_2384217 crossref_primary_10_1038_tpj_2015_17 crossref_primary_10_1001_jamanetworkopen_2023_17037 crossref_primary_10_2478_bjmg_2023_0023 crossref_primary_10_1111_1755_5922_12030 crossref_primary_10_1016_j_rec_2014_01_012 crossref_primary_10_1016_j_ijcard_2012_07_020 crossref_primary_10_1007_s12265_012_9439_7 crossref_primary_10_1007_s40291_013_0022_y crossref_primary_10_1111_j_1365_2125_2012_04328_x crossref_primary_10_1177_1076029619875520 crossref_primary_10_2217_pgs_15_120 crossref_primary_10_1016_j_iccl_2024_06_002 crossref_primary_10_1016_j_wneu_2012_02_040 crossref_primary_10_3390_jpm2040201 crossref_primary_10_1161_CIRCOUTCOMES_113_000321 crossref_primary_10_1016_j_jacc_2015_12_036 crossref_primary_10_1001_jamaneurol_2018_4404 crossref_primary_10_1161_CIRCRESAHA_117_310782 crossref_primary_10_1038_nrneurol_2012_33 crossref_primary_10_1007_s00228_023_03519_y crossref_primary_10_3174_ajnr_A3627 crossref_primary_10_3390_jcm12186074 crossref_primary_10_1161_JAHA_117_005650 crossref_primary_10_18585_inabj_v6i1_41 crossref_primary_10_1016_j_recesp_2011_11_001 crossref_primary_10_1007_s00059_012_3610_4 crossref_primary_10_1016_S0140_6736_19_31276_0 crossref_primary_10_1002_cpt_459 crossref_primary_10_1161_CIRCGENETICS_113_000109 crossref_primary_10_1161_JAHA_112_000131 crossref_primary_10_2459_JCM_0b013e328364bb04 crossref_primary_10_1111_bcp_12230 crossref_primary_10_1111_ene_13962 crossref_primary_10_1016_j_scib_2018_12_020 crossref_primary_10_2147_DDDT_S242167 crossref_primary_10_1002_cpt_331 crossref_primary_10_1111_ijlh_12416 crossref_primary_10_1136_neurintsurg_2014_011357 crossref_primary_10_2459_JCM_0b013e328364bd3a crossref_primary_10_2217_pgs_15_19 crossref_primary_10_1161_CIRCULATIONAHA_111_031195 crossref_primary_10_1016_j_jfma_2014_03_008 crossref_primary_10_1097_MD_0000000000008920 crossref_primary_10_1161_ATVBAHA_114_303275 crossref_primary_10_1016_j_jacc_2013_07_101 crossref_primary_10_1161_CIRCINTERVENTIONS_112_975953 crossref_primary_10_1080_23808993_2020_1746640 crossref_primary_10_1161_CIR_0000000000001257 crossref_primary_10_1080_09537104_2017_1320372 crossref_primary_10_1182_blood_2017_03_742338 crossref_primary_10_1038_nrcardio_2016_101 crossref_primary_10_3174_ajnr_A4388 crossref_primary_10_3340_jkns_2019_0082 crossref_primary_10_1093_ehjcvp_pvae036 crossref_primary_10_1097_FPC_0000000000000177 crossref_primary_10_1002_jcph_225 crossref_primary_10_1016_j_medidd_2020_100038 crossref_primary_10_1160_TH15_12_0981 crossref_primary_10_3390_jpm7040014 crossref_primary_10_1016_j_tig_2012_06_008 crossref_primary_10_2147_PGPM_S324612 crossref_primary_10_1038_nrcardio_2011_206 crossref_primary_10_1002_phar_2758 crossref_primary_10_1186_s13019_025_03380_3 crossref_primary_10_3109_09537104_2013_845874 crossref_primary_10_5551_jat_33290 crossref_primary_10_1097_HCO_0b013e3283606957 crossref_primary_10_1016_j_iccl_2016_08_010 crossref_primary_10_1111_jth_14776 crossref_primary_10_1080_17512433_2017_1353909 crossref_primary_10_1016_j_jjcc_2014_07_016 crossref_primary_10_1111_cge_12881 crossref_primary_10_1161_SVIN_124_001376 crossref_primary_10_1038_clpt_2013_229 crossref_primary_10_2217_ica_12_16 crossref_primary_10_1586_14779072_2013_816120 crossref_primary_10_1016_j_mgene_2014_01_009 crossref_primary_10_1016_j_iccl_2013_05_009 crossref_primary_10_1080_17425255_2022_2166486 crossref_primary_10_1016_j_iccl_2013_05_006 crossref_primary_10_2217_pgs_2016_0008 crossref_primary_10_1016_S0140_6736_12_60161_5 crossref_primary_10_1007_s00101_012_2041_1 crossref_primary_10_2217_pgs_14_17 crossref_primary_10_1016_j_blre_2014_03_004 crossref_primary_10_1161_ATVBAHA_118_311963 crossref_primary_10_1002_cpt_2526 crossref_primary_10_1136_neurintsurg_2013_010809 crossref_primary_10_2217_pgs_12_2 crossref_primary_10_1016_j_ihj_2012_06_002 crossref_primary_10_1016_j_ijcard_2017_03_015 crossref_primary_10_1160_TH15_03_0257 crossref_primary_10_2217_bmm_2016_0070 crossref_primary_10_1146_annurev_pharmtox_051921_092701 crossref_primary_10_2217_pgs_12_67 crossref_primary_10_1161_CIRCINTERVENTIONS_119_007811 crossref_primary_10_1097_HCO_0b013e32835220e3 crossref_primary_10_1177_0267659120978584 crossref_primary_10_1586_14779072_2013_839382 crossref_primary_10_1038_nrcardio_2012_29 crossref_primary_10_1002_cpt_2612 crossref_primary_10_1016_j_ijcard_2016_03_067 crossref_primary_10_1016_j_jtcvs_2012_07_001 crossref_primary_10_1016_j_cjca_2012_02_004 crossref_primary_10_1080_17425255_2017_1363887 crossref_primary_10_1111_cts_12973 crossref_primary_10_1097_HCO_0b013e328353fe5c crossref_primary_10_1586_ecp_12_19 crossref_primary_10_1016_j_prp_2024_155290 crossref_primary_10_1016_j_jstrokecerebrovasdis_2013_06_008 crossref_primary_10_2337_dc11_2351 crossref_primary_10_1016_j_amjcard_2013_05_041 crossref_primary_10_5469_neuroint_2018_01088 crossref_primary_10_1080_09537104_2023_2200860 crossref_primary_10_1016_j_jocn_2012_09_027 crossref_primary_10_1007_s12265_013_9458_z crossref_primary_10_3390_jcm12051799 crossref_primary_10_1016_j_thromres_2016_02_031 crossref_primary_10_1515_dmpt_2018_0006 crossref_primary_10_1111_jth_12318 crossref_primary_10_1155_2013_727842 crossref_primary_10_4244_EIJV9I3A53 crossref_primary_10_1016_j_cjco_2020_11_021 crossref_primary_10_1080_17425255_2021_1925249 crossref_primary_10_1007_s40142_012_0001_3 crossref_primary_10_1007_s11096_013_9783_y crossref_primary_10_12659_MSM_902120 crossref_primary_10_4103_ijp_ijp_53_22 crossref_primary_10_1016_j_jacc_2012_03_034 crossref_primary_10_38124_ijisrt_IJISRT24MAY506 crossref_primary_10_1002_psp4_13053 crossref_primary_10_1016_j_jacc_2012_08_972 crossref_primary_10_2217_ica_12_52 crossref_primary_10_1160_TH12_01_0039 crossref_primary_10_1016_j_thromres_2013_03_017 crossref_primary_10_1182_asheducation_2014_1_343 crossref_primary_10_1373_clinchem_2016_255232 crossref_primary_10_1016_j_thromres_2014_12_007 crossref_primary_10_1016_j_ebiom_2016_02_001 crossref_primary_10_1038_clpt_2012_113 crossref_primary_10_1159_000431261 crossref_primary_10_1586_erc_13_3 crossref_primary_10_1002_sim_5421 crossref_primary_10_1093_eurheartj_eht375 crossref_primary_10_1093_eurheartj_ehs042 crossref_primary_10_1097_MD_0000000000024545 crossref_primary_10_1177_1074248415590196 crossref_primary_10_2217_pgs_2020_0046 crossref_primary_10_1038_s41598_017_16310_8 crossref_primary_10_1160_th15_05_0394 crossref_primary_10_1016_j_jacc_2012_04_045 crossref_primary_10_37882_2223_2966_2020_10_09 crossref_primary_10_1056_NEJMe1911496 crossref_primary_10_1016_j_jacc_2014_04_048 crossref_primary_10_1016_j_thromres_2016_10_008 crossref_primary_10_1002_jcph_17 crossref_primary_10_1161_CIRCGEN_119_002640 crossref_primary_10_1038_clpt_2012_133 crossref_primary_10_1016_j_jacc_2012_11_080 crossref_primary_10_3390_jpm8010008 crossref_primary_10_1016_j_vph_2015_10_005 crossref_primary_10_1160_th15_05_0384 crossref_primary_10_18632_aging_202366 crossref_primary_10_1155_2012_956962 crossref_primary_10_1016_j_jcin_2012_09_013 crossref_primary_10_15829_1560_4071_2022_5021 crossref_primary_10_1124_pr_112_007252 crossref_primary_10_1016_j_jacc_2014_03_051 crossref_primary_10_1007_s11655_017_2551_4 crossref_primary_10_1016_S0140_6736_15_60213_6 crossref_primary_10_1016_j_jcin_2019_03_034 crossref_primary_10_1136_neurintsurg_2016_012635 crossref_primary_10_1097_FJC_0000000000001582 crossref_primary_10_1038_clpt_2012_144 crossref_primary_10_1016_j_clineuro_2024_108229 crossref_primary_10_1161_CIRCULATIONAHA_112_105908 crossref_primary_10_1586_erc_12_1 crossref_primary_10_1177_08971900211049589 crossref_primary_10_1038_s41569_021_00549_w crossref_primary_10_3389_fcvm_2023_1020593 crossref_primary_10_1017_pcm_2023_17 crossref_primary_10_1186_s12883_020_01974_z crossref_primary_10_2165_11640880_000000000_00000 crossref_primary_10_1016_j_jjcc_2013_03_006 crossref_primary_10_1097_HCO_0b013e32835f0bbc crossref_primary_10_1161_CIRCULATIONAHA_111_075242 crossref_primary_10_26683_2304_9359_2019_3_29__27_33 crossref_primary_10_3109_09537104_2015_1095875 crossref_primary_10_1016_j_ahj_2013_04_008 crossref_primary_10_1016_j_jacc_2024_06_038 crossref_primary_10_1016_j_jstrokecerebrovasdis_2018_05_027 crossref_primary_10_4070_kcj_2013_43_8_541 crossref_primary_10_1253_circj_CJ_11_1494 crossref_primary_10_1161_CIR_0000000000000211 crossref_primary_10_1160_TH13_02_0145 crossref_primary_10_1177_03000605211001191 crossref_primary_10_1002_jcph_293 crossref_primary_10_1016_j_athoracsur_2012_07_086 |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS Copyright American Medical Association Nov 23-Nov 30, 2011 |
| Copyright_xml | – notice: 2015 INIST-CNRS – notice: Copyright American Medical Association Nov 23-Nov 30, 2011 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7TS 7U7 7U9 8FD C1K FR3 H94 K9. M7N NAPCQ P64 RC3 7X8 |
| DOI | 10.1001/jama.2011.1703 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Physical Education Index Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts Physical Education Index Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Nursing & Allied Health Premium Genetics Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Virology and AIDS Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-3598 |
| EndPage | 2228 |
| ExternalDocumentID | 2530719831 22088980 24818365 10_1001_jama_2011_1703 1104664 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: K99/R00 HL098461 |
| GroupedDBID | --- -ET -~X .55 .XZ 0R~ 0WA 186 18M 1KJ 1VV 29J 2CT 2FS 2KS 2WC 354 39C 4.4 53G 5GY 5RE 6TJ 85S AAIKC AAMNW AAQQT AAWTL ABBLC ABCQX ABEHJ ABIVO ABOCM ABPMR ABPPZ ABRSH ABWJO ACGFS ACNCT ACPRK ACQAM ADBBV ADUKH AETEA AFCHL AFFDN AFFNX AFHKK AFMIJ AFRAH AGFXO AGHSJ AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BKOMP BRYMA C45 CJ0 CS3 EAM EBS EJD EMOBN EX3 F5P GX1 HF~ KOO KQ8 L7B MVM N4W N9A NEJ NHB NYF OBH OCB OGEVE OHH OK1 OMK OVD P-O P2P PQQKQ QJJ RAJ RNS S10 SJN SV3 TEORI TN5 UBY UHB UKR UMD UPT VVN WH7 WOW X7M XHN XJT XOL XSW XZL YCJ YFH YOC YPV YQT YQY YR2 YRY YSK YYM YZZ ZA5 ZCA ZXP ~H1 AAYXX ACAHW ADXHL ARBJA CITATION YR5 .GJ 1CY 3O- 9M8 AAOGT AAQOH AAYJJ ABDPE ABEFU ACBNA ACCUC ACTDY AI. D0S EBD FA8 H13 IQODW J5H OHT SKT UAP UBC UHU VH1 WHG WOQ YHZ YQI YQJ YXB YYQ ZCG ZGI CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7TS 7U7 7U9 8FD C1K FR3 H94 K9. M7N NAPCQ P64 RC3 7X8 |
| ID | FETCH-LOGICAL-a370t-f851ca14a2f916e05caffc9cfcd7dd9c6b2495fb9d527048f6162a33bf9263773 |
| ISSN | 0098-7484 1538-3598 |
| IngestDate | Fri Sep 05 12:17:01 EDT 2025 Sat Jul 26 02:25:24 EDT 2025 Mon Jul 21 06:04:35 EDT 2025 Mon Jul 21 09:14:01 EDT 2025 Tue Jul 01 01:52:14 EDT 2025 Thu Apr 24 22:51:04 EDT 2025 Fri Jul 05 01:58:19 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 20 |
| Keywords | Human Typing Genotype Patient Cardiovascular disease Posology Antiplatelet agent Medicine Platelet Reactivity Antithrombotic agent Clopidogrel Thienopyridine derivative |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a370t-f851ca14a2f916e05caffc9cfcd7dd9c6b2495fb9d527048f6162a33bf9263773 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 22088980 |
| PQID | 909499428 |
| PQPubID | 42339 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_905962312 proquest_journals_909499428 pubmed_primary_22088980 pascalfrancis_primary_24818365 crossref_primary_10_1001_jama_2011_1703 crossref_citationtrail_10_1001_jama_2011_1703 ama_primary_1104664 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-11-23 |
| PublicationDateYYYYMMDD | 2011-11-23 |
| PublicationDate_xml | – month: 11 year: 2011 text: 2011-11-23 day: 23 |
| PublicationDecade | 2010 |
| PublicationPlace | Chicago, IL |
| PublicationPlace_xml | – name: Chicago, IL – name: United States – name: Chicago |
| PublicationSubtitle | The Journal of the American Medical Association |
| PublicationTitle | JAMA : the journal of the American Medical Association |
| PublicationTitleAlternate | JAMA |
| PublicationYear | 2011 |
| Publisher | American Medical Association |
| Publisher_xml | – name: American Medical Association |
| References | 22416093 - JAMA. 2012 Mar 14;307(10):1024; author reply 1024-5 |
| References_xml | – reference: 22416093 - JAMA. 2012 Mar 14;307(10):1024; author reply 1024-5 |
| SSID | ssj0000137 |
| Score | 2.5352142 |
| Snippet | CONTEXT Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug... Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug... |
| SourceID | proquest pubmed pascalfrancis crossref ama |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2221 |
| SubjectTerms | Aged Aryl Hydrocarbon Hydroxylases - genetics Biological and medical sciences Blood clots Cardiovascular disease Cardiovascular Diseases - drug therapy Cytochrome P-450 CYP2C19 Dose-Response Relationship, Drug Double-Blind Method Drug dosages Female General aspects Genotype Genotype & phenotype Heterozygote Homozygote Humans Male Medical sciences Middle Aged Patients Pharmacogenetics Platelet Activation - drug effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - pharmacology Platelet Function Tests Ticlopidine - administration & dosage Ticlopidine - analogs & derivatives Ticlopidine - pharmacology Treatment Outcome |
| Title | Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease |
| URI | http://dx.doi.org/10.1001/jama.2011.1703 https://www.ncbi.nlm.nih.gov/pubmed/22088980 https://www.proquest.com/docview/909499428 https://www.proquest.com/docview/905962312 |
| Volume | 306 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fi9QwEA7rCSKI6Pmrnh55EHxYerRJN90-yqocJycKd3A-lTRpUKztsrf7cm_3j_m3OZOkbfZ0QYWlLMk0hc7XySSZ-YaQV0LIWWpEHcs0FXGmEx4XQou4hqlawnxZVbYWwelHcXyenVzMLiaTn0HU0mZdHamrP-aV_I9WoQ30ilmy_6DZYVBogP-gX7iChuH6Vzp-27mcWcx60h2snJspzkoaTwAWXz6xRVpgieTO7rP2oZIuggNFlg04mqC3KTiOyleRGKlWfd4beI-YXKW241bDc53etQXzPe3DRAJCiiB3ZTwXuokKSwHs9nhPMDBXyem4K96pr2Cjrxy47AZRJRs9IG9lU-pdL18FYZrjEB-azfcgScCfhelh9xZ-Lh_5qB4NNLIOhhacJyKAKktCg8xcAvZvM0VQocDyuKa55VpYB7BZ_rC4YQxDwVy9qRvc3H3XLXKb5eC7YVDA53lAX8bznih0ZLryD0Maan97yPLrPaN7S1CobIyrrrJ7-WPdoLMH5L5fv9A3DowPyaRu98mdUx-h8YhcO0zSAJPUYpJ2LfWYpD0mKWCSAj6owySK9JikIybpN2j2mKSISeowSbcxST0mH5Pz9-_OFsexL_MRS54n69iA069kmklmYK1SJzMljVGFMkrnWhdKVFgf3VSFnrEcJhwjUsEk55UpmOB5zp-QvbZr62eE1iLh2byQcDvLco3ON5dKK8WSyuSVicg-vOhy6YhcYPWbYHWFiMT9iy-VZ8bHAi1N6Ti9YYWMd6HmStRcRF4P8sNQOyQPt_Q4iLMMHGUuZhE56BVb-i_zsiwSZIzK2DwidOgFq49HebKtuw2KYNUsnrKIPHVwGIf2oHq-s-eA3B2-LfaC7K1Xm_oluNbr6tDi9xfdTNAB |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dosing+clopidogrel+based+on+CYP2C19+genotype+and+the+effect+on+platelet+reactivity+in+patients+with+stable+cardiovascular+disease&rft.jtitle=JAMA+%3A+the+journal+of+the+American+Medical+Association&rft.au=Mega%2C+Jessica+L&rft.au=Hochholzer%2C+Willibald&rft.au=Frelinger%2C+3rd%2C+Andrew+L&rft.au=Kluk%2C+Michael+J&rft.date=2011-11-23&rft.eissn=1538-3598&rft.volume=306&rft.issue=20&rft.spage=2221&rft_id=info:doi/10.1001%2Fjama.2011.1703&rft_id=info%3Apmid%2F22088980&rft.externalDocID=22088980 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0098-7484&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0098-7484&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0098-7484&client=summon |